Stockscreener 앱 받기
2.15
0.47%
0.010
시간 외 거래:
2.11
-0.04
-1.86%
Palisade Bio Inc 주식(PALI)의 최신 뉴스
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView
FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - marketbeat.com
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - marketbeat.com
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - marketbeat.com
Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail
Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia
Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade
Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - marketbeat.com
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative
Palisade Bio Q2 net loss widens on higher R&D costs - TradingView
Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView
Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - marketbeat.com
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Palisade Bio (PALI) Expected to Post Earnings on Monday - marketbeat.com
Perceptive Advisors LLC Has $15.62 Million Stake in Palisade Bio, Inc. $PALI - marketbeat.com
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PALI|Palisade Bio Inc|Price:1.950|Chg%:-0.070 - TradingKey
Palisade Bio, Inc. $PALI Position Trimmed by Commodore Capital LP - marketbeat.com
TradingKey - TradingKey
Palisade Bio Inc (PALI) Institutional Confidence - TradingKey
PALI|Palisade Bio Inc|Price:2.140|Chg%:-0.010 - TradingKey
Palisade Bio Inc. (PALI) Dips 3.5% as Shares Test Key Support at $1.85Reversal Setup Alerts - dars.gov.et
Palisade Bio Inc (PALI) Cash Flow - TradingKey
Palisade Bio, Inc. Revenue Breakdown – NASDAQ:PALI - TradingView
Palisade Bio (PALI) Breaks Below $2.00 as Biotech Sector Headwinds PersistWyckoff Accumulation - po-news-eg.net
PALI Q1 2026 Earnings: EPS Miss Amplifies Investor CautionEarnings Stability Report - dars.gov.et
Enterprise value to revenue forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Benzinga
PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ) - Seeking Alpha
Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Insider Buying: Robert Baltera Acquires 45,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock By Investing.com - Investing.com India
Form 4 Palisade Bio Inc For: 10 July By Investing.com - Investing.com Nigeria
Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock - Investing.com UK
Palisade Bio (PALI) director adds 45,000 shares through July open-market buys - Stock Titan
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum - The Manila Times
Palisade Bio to present clinical updates at Lee... - Pluang
Palisade Bio leaders set to outline IBD drug plans at Boston forum - Stock Titan
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets - Seeking Alpha
Palisade Bio advances gut-restricted PDE4 inhib... - Pluang
Palisade Bio director Robert Baltera Jr. buys $102,084 in stock By Investing.com - Investing.com UK
Insider Buying: Robert Baltera Acquires 50,000 Shares of Palisade Bio Inc (PALI) - GuruFocus
Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com - Investing.com Nigeria
1.80%
1.77%
자본화:
|
볼륨(24시간):